INB-619

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameINB-619

Drug Alias NameINB-619

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD19Immunologic cytotoxicityT lymphocytes stimulants

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune DiseasesLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIN8BIO Inc

China Registration ClassN/A

Develop Information

Active CompaniesIN8BIO Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A